SBI Securities Co. Ltd. Takes $391,000 Position in BioNTech SE (NASDAQ:BNTX)

SBI Securities Co. Ltd. bought a new stake in BioNTech SE (NASDAQ:BNTX) in the 4th quarter, HoldingsChannel reports. The institutional investor bought 3,429 shares of the company’s stock, valued at approximately $391,000.

Other institutional investors also recently modified their holdings of the company. Jones Financial Companies Lllp grew its holdings in shares of BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after acquiring an additional 246 shares in the last quarter. Planning Capital Management Corp grew its holdings in shares of BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after acquiring an additional 450 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of BioNTech by 48.2% in the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after acquiring an additional 300 shares in the last quarter. AlphaCentric Advisors LLC bought a new position in shares of BioNTech in the fourth quarter valued at approximately $168,000. Finally, SVB Wealth LLC bought a new position in shares of BioNTech in the fourth quarter valued at approximately $204,000. 15.52% of the stock is owned by institutional investors.

BioNTech Trading Down 1.7 %

NASDAQ:BNTX opened at $109.65 on Wednesday. The company has a market cap of $26.29 billion, a P/E ratio of -52.21 and a beta of 0.17. The stock’s fifty day moving average price is $117.05 and its two-hundred day moving average price is $112.46. BioNTech SE has a 1 year low of $76.53 and a 1 year high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21.

Analyst Upgrades and Downgrades

BNTX has been the subject of several research reports. JPMorgan Chase & Co. reduced their price objective on BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a report on Tuesday, November 26th. Evercore ISI raised BioNTech from an “in-line” rating to an “outperform” rating and increased their price objective for the company from $110.00 to $125.00 in a report on Tuesday, November 19th. TD Cowen reduced their price objective on BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a report on Tuesday, November 5th. The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and increased their price objective for the company from $90.00 to $137.00 in a report on Friday, November 8th. Finally, Wells Fargo & Company initiated coverage on BioNTech in a report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price objective for the company. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $142.72.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.